Non-small cell lung cancer
Conditions
Interventions
case series:Nil
Sponsors
Hangzhou First People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: From June 2021 to June 2023, NSCLC patients treated with amrotinib in outpatient or inpatient departments of cardiothoracic surgery and respiratory medicine in our hospital mainly had the following inclusion criteria: 1. Patients who voluntarily participated in the study and signed the informed consent; 2. Patients with advanced (IIIB or IV) NSCLC with measurable target lesions; 3. Patients who received >= 2 chemotherapy regimens or were unable to tolerate chemotherapy; 4. For patients with EGFR mutation or ALK mutation positive, amlotinib should be used after progression after receiving the corresponding targeted drug therapy and progression or recurrence after at least 2 systemic chemotherapy; 5. Patients aged 18-75 years, the expected survival time >= 3 months; 6. Anlotinib was given 8mg, 10mg or 12mg every time, once a day, combined for 2 weeks and stopped for 1 week, every 3 weeks as a course of treatment. 7. Enrolled patients were required to extract 2ml of plasma on day 1 of the first cycle of amlotinib administration (30min before administration), day 14 of treatment (30min before administration, 2h, 6h, 10h and 24h after administration) and day 22 (30min before administration of the next cycle), and 2ml of whole blood was collected for DNA extraction. Meanwhile, clinical efficacy and adverse reactions were regularly evaluated.
Exclusion criteria
Exclusion criteria: 1. Patients with previous use of arotinib; 2. Patients with small cell lung cancer, including non-small cell lung cancer and small cell lung cancer; 3. Patients with EGFR gene mutation or ALK mutation were not treated with corresponding targeted drugs; 4. Patients scheduled for systemic anti-tumor therapy before or within 4 weeks of this study, including cytotoxic drugs, signal transduction inhibitors and immunotherapy (or 6 weeks before administration); The patients were treated with ef-rt four weeks before the treatment, and the patients were treated with limited radiotherapy two weeks before the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| security; | — |
Countries
China
Contacts
Public ContactJiang Lou
Hangzhou First People's Hospital
Outcome results
None listed